Table 3.
Best overall response
| PF-07209960 dose levels |
Total (N = 29) | ||||||
|---|---|---|---|---|---|---|---|
| 1 mg (n = 3) | 3 mg (n = 4) | 10 mg (n = 3) | 15 mg (n = 3) | 20 mg (n = 11) | 30 mg (n = 5) | ||
| Confirmed best overall response, n (%) | |||||||
| Complete response (CR) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Partial response (PR) | 0 | 0 | 0 | 0 | 1 (9.1) | 1 (20.0) | 2 (6.9) |
| Stable disease (SD) | 2 (66.7) | 3 (75.0) | 2 (66.7) | 0 | 4 (36.4) | 1 (20.0) | 12 (41.4) |
| Progressive disease (PD) | 1 (33.3) | 0 | 1 (33.3) | 3 (100.0) | 6 (54.5) | 3 (60.0) | 14 (48.3) |
| Non-CR/non-PD | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Non-evaluable (NE)a | 0 | 1 (25.0) | 0 | 0 | 0 | 0 | 1 (3.4) |
| Objective response (CR + PR), n (%) | 0 | 0 | 0 | 0 | 1 (9.1) | 1 (20.0) | 2 (6.9) |
| 95% CI | 0.0-70.8 | 0.0-60.2 | 0.0-70.8 | 0.0-70.8 | 0.2-41.3 | 0.5-71.6 | 0.8-22.8 |
| Disease control | |||||||
| CR + PR + SD + non-CR/non-PD, n (%) | 2 (66.7) | 3 (75.0) | 2 (66.7) | 0 | 5 (45.5) | 2 (40.0) | 14 (48.3) |
| 95% CI | 9.4-99.2 | 19.4-99.4 | 9.4-99.2 | 0.0-70.8 | 16.7-76.6 | 5.3-85.3 | 29.4-67.5 |
CI, confidence interval.
a
Reason for NE was SD too early.